メタ情報
| meta description平均長 | 63.2 |
|---|
| OGPありページ数 | 0 |
|---|
| Twitterカードありページ数 | 0 |
|---|
内部リンク分析（Internal）
| ユニーク内部リンク数 | 20 |
|---|
| ページあたり内部リンク平均 | 12.07 |
|---|
連絡先候補（Contacts）
このデータの閲覧には会員登録が必要になります。会員登録
キーワード分析（KeywordMap）
ワードクラウド上位
| 語 | 重み |
|---|
| cancer | 1 |
| cells | 0.96 |
| mAb | 0.670742 |
| h4713 | 0.655625 |
| antibodies | 0.535767 |
| mAbs | 0.491719 |
| method | 0.491719 |
| lymphoma | 0.487812 |
| molecules | 0.487812 |
| antigens | 0.409766 |
| not | 0.4 |
| which | 0.389648 |
| cell | 0.389648 |
| can | 0.365859 |
| drugs | 0.327812 |
| after | 0.327812 |
| immunizing | 0.327812 |
| HLA | 0.304883 |
| therapeutic | 0.304883 |
| also | 0.292236 |
| will | 0.28 |
| methods | 0.245859 |
| recognise | 0.245859 |
| dimensional | 0.245859 |
| affinity | 0.245859 |
| target | 0.245859 |
| lines | 0.245859 |
| direct | 0.245859 |
| have | 0.243906 |
| minutes | 0.243906 |
| only | 0.243906 |
| malignant | 0.243906 |
| class | 0.243906 |
| agents | 0.243906 |
| three | 0.243906 |
| against | 0.24353 |
| antibody | 0.24353 |
| surface | 0.24353 |
| developing | 0.194824 |
| making | 0.194824 |
| Matsuoka | 0.194824 |
| but | 0.194824 |
| しかし | 0.18293 |
| 日本抗体医薬株式会社 | 0.18293 |
| drug | 0.18293 |
| most | 0.18293 |
| patients | 0.18293 |
| treatment | 0.18293 |
| high | 0.18293 |
| hole | 0.18293 |
共起語上位
| 語1 | 語2 | スコア | 共起ページ数 |
|---|
| Close | MENU | 3.844566 | 60 |
| Therapeutics | mab | 3.256319 | 42 |
| h4713 | mAb | 2.85602 | 32 |
| Inc | Therapeutics | 2.763894 | 27 |
| Inc | mab | 2.411675 | 26 |
| dimensional | three | 2.139394 | 12 |
| 嘉展 | 岡田 | 2.095699 | 8 |
| Okada | Yoshinobu | 2.095699 | 8 |
| HLA | class | 2.044059 | 13 |
| 代表取締役 | 岡田 | 1.994174 | 8 |
| Juntendo | University | 1.994174 | 8 |
| President | Yoshinobu | 1.994174 | 8 |
| photo | shows | 1.994174 | 8 |
| Antibody | Drug | 1.994174 | 8 |
| Conjugates | Drug | 1.994174 | 8 |
| BMC | Res | 1.994174 | 8 |
| Notes | Res | 1.994174 | 8 |
| chains | sugar | 1.994174 | 8 |
| peptide | sequences | 1.994174 | 8 |
| changes | morphological | 1.994174 | 8 |
| agents | therapeutic | 1.937445 | 12 |
| addition | after | 1.860853 | 9 |
| 代表取締役 | 日本抗体医薬株式会社 | 1.809697 | 8 |
| hole | large | 1.809697 | 8 |
| conventional | methods | 1.809697 | 8 |
| dimensional | structure | 1.809697 | 8 |
| ONE | PLoS | 1.809697 | 8 |
| BMC | ONE | 1.809697 | 8 |
| advantage | has | 1.809697 | 8 |
| cell | lines | 1.752186 | 12 |
| cells | lymphoma | 1.726303 | 28 |
| large | making | 1.678809 | 8 |
| addition | minutes | 1.678809 | 8 |
| Matsuoka | PLoS | 1.678809 | 8 |
| 代表取締役 | 嘉展 | 1.642251 | 6 |
| Okada | President | 1.642251 | 6 |
| discovery | drug | 1.62522 | 8 |
| affinity | high | 1.62522 | 8 |
| 以下 | 当社 | 1.593022 | 5 |
| といいます | 以下 | 1.593022 | 5 |
| 以下 | 個人情報 | 1.593022 | 5 |
| antigens | including | 1.577284 | 8 |
| lymphoma | malignant | 1.570708 | 12 |
| addition | h4713 | 1.560204 | 9 |
| Antibody | Conjugates | 1.557393 | 6 |
| BMC | PLoS | 1.557393 | 6 |
| BMC | Notes | 1.557393 | 6 |
| お問い合わせはこちらのフォーム | またはメールからお願いいたします | 1.544406 | 4 |
| inquiries | types | 1.544406 | 4 |
| Laps | Video | 1.544406 | 4 |